{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T07:10:59Z","timestamp":1792393859920,"version":"4.4.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T00:00:00Z","timestamp":1768089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T00:00:00Z","timestamp":1768089600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100013226","name":"Pierre Fabre Laboratories","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100013226","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cancer treatments often cause skin toxicities that disrupt therapy and reduce patients\u2019 quality of life, yet research on their management in the Middle East is scarce. This study aims to examine the practices and challenges of managing skin-related adverse effects in cancer patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A mixed-method survey was conducted on a sample of dermatologists and oncologists practicing in Middle Eastern countries who were invited to participate in\u00a0Pierre Fabre's  annual Middle East Medical Convention. A brief online questionnaire, distributed to 250 dermatologists and 19 oncologists, using both quantitative and qualitative approaches, assessed the frequency, types, and management of skin conditions, alongside perceived barriers and referral practices.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The study included responses from 117 dermatologists and 19 oncologists. Oncologists encountered cancer-related skin manifestations considerably more often, with 44.4% seeing such cases daily compared to 8.1% of dermatologists (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Notable differences were also observed in the types of skin conditions reported, such as nail changes, which were significantly more frequent among dermatologists (72.6% vs. 31.6%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), whereas hand-foot syndrome was markedly more commonly observed among oncologists (89.5% vs. 6.0%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Dermatologists reported feeling very comfortable managing these conditions more often than oncologists (50.4% vs. 10.5%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.004). Key barriers included the severity of skin conditions, selecting appropriate dermo-cosmetic products, and limited knowledge in onco-dermatology. The qualitative analysis highlighted oncologists\u2019 challenges in managing skin toxicities under three main themes: (1) preventing cancer treatment interruptions, (2) limited specialized dermatologic knowledge and support, and (3) addressing patient-centered issues.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Findings reveal differing perspectives between dermatologists and oncologists and underscore the need for greater collaboration to optimize the management of cancer-related skin toxicities.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00520-025-10254-w","type":"journal-article","created":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T00:32:20Z","timestamp":1768091540000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Perspectives on managing skin manifestations in cancer patients: a multidisciplinary mixed-method survey of oncologists and dermatologists"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1925-1243","authenticated-orcid":false,"given":"Davide","family":"Fattore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omalkhair","family":"Abulkhair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola M.","family":"Reda Khorshid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanios","family":"Bou Khalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rania H.","family":"Kafrouny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6438-0159","authenticated-orcid":false,"given":"Michele","family":"Cherfane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,11]]},"reference":[{"issue":"5","key":"10254_CR1","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ijwd.2019.10.003","volume":"5","author":"MN Ferreira","year":"2019","unstructured":"Ferreira MN, Ramseier JY, Leventhal JS (2019) Dermatologic conditions in women receiving systemic cancer therapy. Int J Womens Dermatol 5(5):285\u2013307","journal-title":"Int J Womens Dermatol"},{"issue":"7","key":"10254_CR2","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1177\/1078155220936341","volume":"26","author":"D Silva","year":"2020","unstructured":"Silva D, Gomes A, Ms Lobo J, Almeida V, Almeida IF (2020) Management of skin adverse reactions in oncology. J Oncol Pharm Pract 26(7):1703\u20131714","journal-title":"J Oncol Pharm Pract"},{"issue":"Suppl 1","key":"10254_CR3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s40257-018-0384-3","volume":"19","author":"M Lacouture","year":"2018","unstructured":"Lacouture M, Sibaud V (2018) Toxic side effects of targeted therapies and immunotherapies affecting the skin, oral mucosa, hair, and nails. Am J Clin Dermatol 19(Suppl 1):31\u201339","journal-title":"Am J Clin Dermatol"},{"issue":"14","key":"10254_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16142526","volume":"16","author":"R Ladwa","year":"2024","unstructured":"Ladwa R, Fogarty G, Chen P, Grewal G, McCormack C, Mar V, Kerob D, Khosrotehrani K (2024) Management of skin toxicities in cancer treatment: an Australian\/New Zealand perspective. Cancers (Basel) 16(14):2526","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10254_CR5","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1111\/ijd.15081","volume":"60","author":"HJ Suh","year":"2021","unstructured":"Suh HJ, Fl\u00f3rez \u00c1, Sacrist\u00e1n V, Rodr\u00edguez Martinez \u00c1, Fern\u00e1ndez F, Vilanova-Trillo L, Constenla M, Pereiro M (2021) Cutaneous adverse events in patients receiving anticancer therapy in a tertiary hospital setting: the old and the new. Int J Dermatol 60(2):208\u2013216","journal-title":"Int J Dermatol"},{"issue":"12","key":"10254_CR6","first-page":"9681","volume":"30","author":"T Behroozian","year":"2022","unstructured":"Behroozian T, Fatima S, Finkelstein S, Kanee L, Bonomo P, Wolf JR, Vassiliou V, van den Hurk C, Chow E, Beveridge M (2022) Current quality of life assessment tools may not fully address dermatological adverse events from anti-cancer therapies. Support Care Cancer 30(12):9681\u20139685","journal-title":"Support Care Cancer"},{"issue":"1","key":"10254_CR7","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1111\/j.1468-3083.2012.04466.x","volume":"27","author":"HS Ra","year":"2013","unstructured":"Ra HS, Shin SJ, Kim JH, Lim H, Cho BC, Roh MR (2013) The impact of dermatological toxicities of anti-cancer therapy on the dermatological quality of life of cancer patients. J Eur Acad Dermatol Venereol 27(1):e53\u2013e59","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"Suppl 5","key":"10254_CR8","first-page":"34","volume":"21","author":"LI Wagner","year":"2007","unstructured":"Wagner LI, Lacouture ME (2007) Dermatologic toxicities associated with EGFR inhibitors: the clinical psychologist\u2019s perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae. Oncology (Williston Park) 21(Suppl 5):34\u201336","journal-title":"Oncology (Williston Park)"},{"issue":"4","key":"10254_CR9","first-page":"545","volume":"19","author":"AC Haley","year":"2011","unstructured":"Haley AC, Calahan C, Gandhi M, West DP, Rademaker A, Lacouture ME (2011) Skin care management in cancer patients: an evaluation of quality of life and tolerability. Support Care Cancer 19(4):545\u2013554","journal-title":"Support Care Cancer"},{"issue":"5","key":"10254_CR10","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.jaad.2020.10.047","volume":"85","author":"JJ Yang","year":"2021","unstructured":"Yang JJ, So N, Maloney NJ, Arzeno J, Clifton KK, Bach DQ (2021) Inadequate and delayed characterization of cutaneous reactions for US Food and Drug Administration-approved oncologic drugs from 2011-2020 leading to medication discontinuation. J Am Acad Dermatol 85(5):1351\u20131352","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10254_CR11","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s13555-019-0296-z","volume":"9","author":"KA Lowe","year":"2019","unstructured":"Lowe KA, Sangar\u00e9 L, Bergstresser R, McNamara M, Kafatos G, Garawin T (2019) A national survey of medical oncologist\u2019s opinions and perceptions for managing rash among mCRC patients treated with panitumumab. Dermatol Ther (Heidelb) 9(2):337\u2013353","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10254_CR12","doi-asserted-by":"crossref","unstructured":"Lacouture ME, Sibaud V, Gerber PA, van den Hurk C, Fern\u00e1ndez-Pe\u00f1as P, Santini D, Jahn F, Jordan K (2021) ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines\u2606. Ann Oncol 32(2):157\u2013170","DOI":"10.1016\/j.annonc.2020.11.005"},{"issue":"10","key":"10254_CR13","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1111\/jdv.16849","volume":"34","author":"C Garbe","year":"2020","unstructured":"Garbe C, Peris K, Soura E, Forsea AM, Hauschild A, Arenbergerova M, Bylaite M, Del Marmol V, Bataille V, Samimi M, Gandini S, Saiag P, Eigentler TK, Lallas A, Zalaudek I, Lebbe C, Grob JJ, Hoeller C, Robert C, Dr\u00e9no B, Arenberger P, Kandolf-Sekulovic L, Kaufmann R, Malvehy J, Puig S, Leiter U, Ribero S, Papadavid E, Quaglino P, Bagot M, John SM, Richard MA, Trakatelli M, Salavastru C, Borradori L, Marinovic B, Enk A, Pincelli C, Ioannides D, Paul C, Stratigos AJ (2020) The evolving field of dermato-oncology and the role of dermatologists: position paper of the EADO, EADV and task forces, EDF, IDS, EBDV-UEMS and EORTC cutaneous lymphoma task force. J Eur Acad Dermatol Venereol 34(10):2183\u20132197","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"10254_CR14","volume":"31","author":"B Dreno","year":"2023","unstructured":"Dreno B, Khosrotehrani K, De Barros Silva G, Wolf JR, Kerob D, Trombetta M, Atenguena E, Dielenseger P, Pan M, Scotte F, Krakowski I, Lacouture M (2023) The role of dermocosmetics in the management of cancer-related skin toxicities: international expert consensus. Support Care Cancer 31(12):672","journal-title":"Support Care Cancer"},{"issue":"3","key":"10254_CR15","doi-asserted-by":"publisher","first-page":"274","DOI":"10.23736\/S2784-8671.23.07531-X","volume":"158","author":"D Fattore","year":"2023","unstructured":"Fattore D, Fabbrocini G, Sibaud V, Sollena P (2023) The urgent need of dermatologists for cancer patients in Italy. Ital J Dermatol Venereol 158(3):274\u2013275","journal-title":"Ital J Dermatol Venereol"},{"issue":"9","key":"10254_CR16","first-page":"4931","volume":"29","author":"V Long","year":"2021","unstructured":"Long V, Choi EC, Tan CL (2021) Supportive oncodermatology-a narrative review of its utility and the way forward. Support Care Cancer 29(9):4931\u20134937","journal-title":"Support Care Cancer"},{"issue":"4","key":"10254_CR17","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s40257-022-00705-z","volume":"23","author":"AS Bang","year":"2022","unstructured":"Bang AS, Anadkat MJ, Choi JN, LeBoeuf NR, Jung JY, Markova A, Gordon A, Rossi AM, Noor SJ, Sibaud V, Lacouture ME (2022) Oncodermatology: advancing the science and care of cancer patients and survivors. Am J Clin Dermatol 23(4):587\u2013589","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"10254_CR18","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.jaad.2010.06.051","volume":"65","author":"Y Balagula","year":"2011","unstructured":"Balagula Y, Rosen ST, Lacouture ME (2011) The emergence of supportive oncodermatology: the study of dermatologic adverse events to cancer therapies. J Am Acad Dermatol 65(3):624\u2013635","journal-title":"J Am Acad Dermatol"},{"key":"10254_CR19","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1200\/EDBK_289911","volume":"40","author":"A Deutsch","year":"2020","unstructured":"Deutsch A, Leboeuf NR, Lacouture ME, McLellan BN (2020) Dermatologic adverse events of systemic anticancer therapies: cytotoxic chemotherapy, targeted therapy, and immunotherapy. Am Soc Clin Oncol Educ Book 40:485\u2013500","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"3","key":"10254_CR20","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1111\/jdv.17855","volume":"36","author":"Z Apalla","year":"2022","unstructured":"Apalla Z, Nikolaou V, Fattore D, Fabbrocini G, Freites-Martinez A, Sollena P, Lacouture M, Kraehenbuehl L, Stratigos A, Peris K, Lazaridou E, Richert B, Vigarios E, Riganti J, Baroudjian B, Filoni A, Dodiuk-Gad R, Lebb\u00e9 C, Sibaud V (2022) European recommendations for management of immune checkpoint inhibitors-derived dermatologic adverse events. The EADV task force \u201cDermatology for cancer patients\u201d position statement. J Eur Acad Dermatol Venereol 36(3):332\u2013350","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10254_CR21","doi-asserted-by":"publisher","DOI":"10.1177\/2050312118822927","author":"Y Chun Tie","year":"2019","unstructured":"Chun Tie Y, Birks M, Francis K (2019) Grounded theory research: a design framework for novice researchers. SAGE Open Med. https:\/\/doi.org\/10.1177\/2050312118822927","journal-title":"SAGE Open Med"},{"issue":"8","key":"10254_CR22","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1080\/0142159X.2020.1755030","volume":"42","author":"ME Kiger","year":"2020","unstructured":"Kiger ME, Varpio L (2020) Thematic analysis of qualitative data: AMEE guide no. 131. Med Teach 42(8):846\u2013854","journal-title":"Med Teach"},{"issue":"4","key":"10254_CR23","first-page":"149","volume":"8","author":"Y Balagula","year":"2010","unstructured":"Balagula Y, Lacouture ME, Cotliar JA (2010) Dermatologic toxicities of targeted anticancer therapies. J Support Oncol 8(4):149\u2013161","journal-title":"J Support Oncol"},{"issue":"3","key":"10254_CR24","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s40257-017-0336-3","volume":"19","author":"V Sibaud","year":"2018","unstructured":"Sibaud V (2018) Dermatologic reactions to immune checkpoint inhibitors\u202f: skin toxicities and immunotherapy. Am J Clin Dermatol 19(3):345\u2013361","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"10254_CR25","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1111\/jdv.16159","volume":"34","author":"DM Barrios","year":"2020","unstructured":"Barrios DM, Phillips GS, Freites-Martinez A, Hsu M, Ciccolini K, Skripnik Lucas A, Marchetti MA, Rossi AM, Lee EH, Deng L, Markova A, Myskowski PL, Lacouture ME (2020) Outpatient dermatology consultations for oncology patients with acute dermatologic adverse events impact anticancer therapy interruption: a retrospective study. J Eur Acad Dermatol Venereol 34(6):1340\u20131347","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"10254_CR26","first-page":"e61","volume":"11","author":"B Nardone","year":"2012","unstructured":"Nardone B, Hensley JR, Kulik L, West DP, Mulcahy M, Rademaker A, Lacouture ME (2012) The effect of hand-foot skin reaction associated with the multikinase inhibitors sorafenib and sunitinib on health-related quality of life. J Drugs Dermatol 11(11):e61\u2013e65","journal-title":"J Drugs Dermatol"},{"issue":"7","key":"10254_CR27","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S1470-2045(05)70243-6","volume":"6","author":"C Robert","year":"2005","unstructured":"Robert C, Soria JC, Spatz A, Le Cesne A, Malka D, Pautier P, Wechsler J, Lhomme C, Escudier B, Boige V, Armand JP, Le Chevalier T (2005) Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 6(7):491\u2013500","journal-title":"Lancet Oncol"},{"issue":"4","key":"10254_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007675","volume":"12","author":"ST Chen","year":"2024","unstructured":"Chen ST, Semenov YR, Alloo A, Bach DQ, Betof Warner A, Bougrine A, Burton L, Cappelli LC, Castells M, Cohen J, Dewan AK, Fadden R, Guggina L, Hegde A, Huang V, Johnson DB, Kaffenberger B, Kroshinsky D, Kwatra S, Kwong B, Lacouture ME, Larocca C, Leventhal J, Markova A, McDunn J, Mooradian MJ, Naidoo J, Choi J, Nambudiri V, Nelson CA, Patel AB, Pimkina J, Rine J, Rubin KM, Sauder M, Shaigany S, Shariff A, Sullivan RJ, Zubiri L, Reynolds KL, LeBoeuf NR (2024) Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy. J Immunother Cancer 12(4):e007675","journal-title":"J Immunother Cancer"},{"issue":"4","key":"10254_CR29","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.jaad.2019.09.026","volume":"82","author":"ST Chen","year":"2020","unstructured":"Chen ST, Molina GE, Lo JA, Durbin S, Cohen JV, Reynolds KL, Kroshinsky D (2020) Dermatology consultation reduces interruption of oncologic management among hospitalized patients with immune-related adverse events: a retrospective cohort study. J Am Acad Dermatol 82(4):994\u2013996","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10254_CR30","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.jaad.2020.08.005","volume":"85","author":"AM Rossi","year":"2021","unstructured":"Rossi AM, Hibler BP, Navarrete-Dechent C, Lacouture ME (2021) Restorative oncodermatology: diagnosis and management of dermatologic sequelae from cancer therapies. J Am Acad Dermatol 85(3):693\u2013707","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10254_CR31","doi-asserted-by":"publisher","first-page":"477","DOI":"10.36849\/JDD.2020.5040","volume":"19","author":"L Aizman","year":"2020","unstructured":"Aizman L, Nelson K, Sparks AD, Friedman AJ (2020) The influence of supportive oncodermatology interventions on patient quality of life: a cross-sectional survey. J Drugs Dermatol 19(5):477\u2013482","journal-title":"J Drugs Dermatol"},{"issue":"5","key":"10254_CR32","doi-asserted-by":"publisher","first-page":"e440","DOI":"10.1111\/jdv.19679","volume":"38","author":"A Freites-Martinez","year":"2024","unstructured":"Freites-Martinez A, Apalla Z, Fattore D, Fida M, Bang AS, Smith J, Babakoohi S, Lacouture M, Sibaud V (2024) Supportive oncodermatology practices in Europe and the USA. J Eur Acad Dermatol Venereol 38(5):e440\u2013e443","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3-4","key":"10254_CR33","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1159\/000112795","volume":"72","author":"SL Boone","year":"2007","unstructured":"Boone SL, Rademaker A, Liu D, Pfeiffer C, Mauro DJ, Lacouture ME (2007) Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results. Oncology 72(3\u20134):152\u2013159","journal-title":"Oncology"},{"issue":"1","key":"10254_CR34","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.abd.2021.05.007","volume":"97","author":"WQGW Ceglio","year":"2022","unstructured":"Ceglio WQGW, Rebeis MM, Santana MF, Miyashiro D, Cury-Martins J, Sanches JA (2022) Cutaneous adverse events to systemic antineoplastic therapies: a retrospective study in a public oncologic hospital. An Bras Dermatol 97(1):14\u201321","journal-title":"An Bras Dermatol"},{"issue":"9","key":"10254_CR35","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1111\/jdv.12082","volume":"27","author":"B Dreno","year":"2013","unstructured":"Dreno B, Bensadoun RJ, Humbert P, Krutmann J, Luger T, Triller R, Rougier A, Seit\u00e9 S (2013) Algorithm for dermocosmetic use in the management of cutaneous side-effects associated with targeted therapy in oncology. J Eur Acad Dermatol Venereol 27(9):1071\u20131080","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"10254_CR36","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1111\/jdv.20228","volume":"38","author":"E Parriel","year":"2024","unstructured":"Parriel E, Sibaud V (2024) Supportive oncodermatology is the key! J Eur Acad Dermatol Venereol 38(9):1675\u20131676","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"10254_CR37","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.4143\/crt.2017.435","volume":"50","author":"J Lee","year":"2018","unstructured":"Lee J, Lim J, Park JS, Kim M, Kim TY, Kim TM, Lee KH, Keam B, Han SW, Mun JH, Cho KH, Jo SJ (2018) The impact of skin problems on the quality of life in patients treated with anticancer agents: a cross-sectional study. Cancer Res Treat 50(4):1186\u20131193","journal-title":"Cancer Res Treat"},{"issue":"1","key":"10254_CR38","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.1016\/j.jaad.2011.02.026","volume":"67","author":"SY Chon","year":"2012","unstructured":"Chon SY, Champion RW, Geddes ER, Rashid RM (2012) Chemotherapy-induced alopecia. J Am Acad Dermatol 67(1):e37-47","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10254_CR39","first-page":"139","volume":"5","author":"K M\u00fcnstedt","year":"1997","unstructured":"M\u00fcnstedt K, Manthey N, Sachsse S, Vahrson H (1997) Changes in self-concept and body image during alopecia induced cancer chemotherapy. Support Care Cancer 5(2):139\u2013143","journal-title":"Support Care Cancer"},{"key":"10254_CR40","doi-asserted-by":"publisher","unstructured":"Fattore D, Lauletta G, Apalla Z, Sibaud V, Freites-Martinez A (2024) Dermatologic immune-related adverse events: it is time for a game change! J Eur Acad Dermatol Venereol. https:\/\/doi.org\/10.1111\/jdv.20282","DOI":"10.1111\/jdv.20282"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-10254-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-025-10254-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-10254-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T20:04:05Z","timestamp":1771272245000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-025-10254-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,11]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10254"],"URL":"https:\/\/doi.org\/10.1007\/s00520-025-10254-w","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,11]]},"assertion":[{"value":"9 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the ethical principles of the Declaration of Helsinki. Approval for the study was obtained from the Medical and Compliance Department of Pierre Fabre Laboratories, Middle East, as well as from the Institutional Review Board of the Lebanese American University (LAU.SOM.MC1.23).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from participants and was implied by the voluntary completion and submission of the survey.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"TB and RK are employees of the sponsoring company. However, they declare no competing interests related to this work, as the study is observational and descriptive in nature and does not involve any intervention or product evaluation.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"82"}}